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ABSTRACT
Introduction: Meta-analyses are useful to
increase knowledge and strengthen evidence
about antidepressant treatment supplementary
to individual studies.
Methods: A pooled analysis of four multicenter,
open-label, prospective, non-interventional
studies (2009–2013) was performed to provide
further evidence about the antidepressant
effectiveness and tolerability of agomelatine
(25–50 mg/day) in a large number of non-se-
lected German outpatients with major depres-
sive disorder. The main analysis was performed
after 12 weeks (n = 9601) and in subpopulations
after 24 and 52 weeks by descriptive statistical
methods.
Results: Overall, 60.1% of patients were pre-
treated with antidepressants. Concomitant psy-
chiatric diseases (71.9%), co-medication with
antidepressants (18.9%) and/or psychotropic
medication (31.9%) were observed. Depressive
symptoms improved according to the Clinical
Global Impression (CGI) in 81% after 12 weeks,
a response was observed in 78.7% (CGI-I B2),
and remission in 34.5% of patients
(CGI-S = 1 or 2). In subpopulations, response
was documented in 79.3% (W24) and 75.9%
(W52) and remission in 38.1% (W24) and 47.5%
(W52), respectively. Over 12 weeks, adverse drug
reactions (ADRs) were reported for 511 patients
(5.32%), most frequently headache (0.92%) and
nausea (0.75%), and serious adverse drug reac-
tions (sADR) for 18 patients (0.19%). Between
W12–W24 and W24–W52, ADRs were reported
for 0.49%/0.99% and sADRs for 0.05%/0%,
respectively. Overall, 49 patients (0.5%) showed
clinically relevant transaminase elevations (AST/
ALT [3 times upper normal value), with 19
patients (0.2%) showing preexisting elevations
at the study start. One patient (0.03%) devel-
oped hepatitis with reversible symptoms after
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treatment discontinuation. ADR predominantly
occurred within the first weeks of treatment.
Mean weight and body mass index (BMI)
remained unchanged over 24 weeks.
Conclusion: In this pooled data analysis, 9601
depressed patients of clinical practice were
evaluated over 12 weeks and subpopulations
were also analyzed over 24 and 52 weeks.
Agomelatine effectively reduced depressive
symptoms (CGI-response and remission) with
good general tolerability.
Keywords: Agomelatine; BMI; Dosage;
Effectiveness; Liver function; Major depression;
Pooled analysis; Tolerability
INTRODUCTION
In addition to individual clinical trials,
meta-analyses and pooled analyses are used for
evidence-based evaluation of therapeutic inter-
ventions in depression to extend knowledge
about treatment options and analyze specific
data based on a larger sample size. In general,
efficacy and tolerability of drugs are examined
and confirmed by randomized controlled trials
(RCTs) with narrowly defined patient collec-
tives, under strict inclusion and exclusion cri-
teria, and with a precisely defined therapeutic
regimen. Therefore controlled trials may not
fully represent real-world patients in daily
practice. In psychiatric care, psychotropic
co-medication also represents a risk for comor-
bid and elderly patients as a result of pharma-
cological interactions or possible effects on
existing somatic diseases. Therefore non-inter-
ventional studies can provide relevant infor-
mation in addition to existing evidence of
RCTs, because heterogeneous patient popula-
tions are observed in everyday clinical practice.
In order to collect realistic data on agome-
latine treatment of comorbid and co-medicated
depressed patients, four non-interventional
studies were performed in an ambulant setting
in Germany between 2009 and 2013.
The antidepressant agomelatine is a mela-
tonergic receptor agonist (MT1/MT2) and an
antagonist at the postsynaptic serotonin recep-
tor 5-HT2c [1, 2]. Its mode of action may be
explained by the synergy of MT1/MT2 and
5-HT2C receptors, which increases noradrener-
gic and dopaminergic neurotransmission, and a
specific release of noradrenaline and dopamine
has been described in the prefrontal cortex
without effect on the extracellular levels of
serotonin [3–5]. In addition, an increase of
neurotrophic factors (e.g., brain-derived neu-
rotrophic factor, BDNF) and a decrease in
stress-related glutamate elevation have also
been described [2, 6, 7] as well as resynchro-
nization of circadian rhythms [8–10].
After oral intake, agomelatine is rapidly and
well absorbed (C80%) with low absolute
bioavailability (\5%) and substantial interindi-
vidual variability. Peak plasma concentration is
reached after 1–2 h and mean plasma half-life is
between 1 and 2 h. Agomelatine is rapidly
metabolized, mainly by hepatic CYP1A2,
CYP2C9, and CYP2C19, and inactive metabolites
are eliminated in the urine. Agomelatine does
not inhibit or induce CYP450 isoenzymes and
will not modify exposure of medicinal products
metabolized by CYP450. Additionally it is not a
substrate, inducer, or inhibitor of P-glycoprotein
(P-gp) [11–13]. Antidepressant efficacy and tol-
erability of agomelatine are confirmed in
numerous clinical studies [10, 14–27].
The objective of this pooled analysis was an
evaluation of agomelatine therapy in a large
number of unselected patients in daily practice
in order to gain information about the natu-
ralistic treatment situation of patients with
depression. This large sample size enables a
valuable assessment of effectiveness, dosage,
evolution of body weight, and rare or yet
unknown adverse drug reactions (ADRs). Since
monitoring of hepatic transaminases is recom-
mended for agomelatine-treated patients, the
presented data particularly focus on the analysis
of incidence and course of hepatic transaminase
elevation under daily treatment conditions.
METHODS
Study Design and Population
The presented analysis was performed by pool-
ing Germany-wide data collected by 1772
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psychiatrists or specialized general practitioners
(GPs) between 2009 and 2013. Overall 9601
outpatients of four prospective, multicentric,
open-label, non-interventional studies with
agomelatine were analyzed over a minimum of
12 to a maximum of 52 weeks (follow-up of
VIVALDI study): VIVALDI (Valdoxan Improves
depressiVe symptoms And normaLizes circa-
DIan rhythms) and VIVALDI follow-up (2009/
2010) [28–31] were performed exclusively in
patients treated by psychiatrists, VIVALDI
Praxis (2010) [32] only in GPs practices, VITAL
(Valdoxan Improves Treatment of depression
and daytime Activity in real Life; 2011–2012)
[33], and VIVRE (Valdoxan ImproVes depRes-
sion with anxiEty symptoms; 2012–2013) [34]
with psychiatrists and specialized GPs.
Data Collection
The pooled analysis includes all original data
that had been collected in each of the individ-
ual studies in an identical or comparable way at
a corresponding time of investigation. At the
baseline visit (week 0), demographic data (age,
sex, weight, smoking status), past psychiatric
history (number of prior depressive episodes,
duration of current episode, psychiatric
comorbidities, previous suicide attempts), and
form of therapy (pretreatment with antidepres-
sants, psychotropic co-medication) were
documented.
The antidepressant effect in all four included
studies was assessed using the 7-point clinician
rating scale Clinical Global Impression (CGI).
Rater training had been offered to doctors in two
studies to improve quality of assessment. Physi-
cians evaluated severity of disease
(CGI-S = Severity Scale; from 1 = ‘‘normal, not at
all ill’’ to 7 = ‘‘most extremely ill’’) and
improvement or worsening of disease
(CGI-I = Improvement Scale; from 1 = ‘‘very
much improved’’ to 7 = ‘‘very much worse’’);
response (CGI-IB2) and remission rates (CGI-S =
1 or 2) were analyzed.
Tolerability data including the incidence and
type of adverse drug reactions (ADR) were ana-
lyzed. Physicians were asked to document
emergent ADR at each visit with standardized
ADR documentation sheets according to Ger-
man and European pharmacovigilance require-
ments. All ADRs were reported to BfArM
(Bundesinstitut fu¨r Arzneimittel und Medizin-
produkte) in accordance with applicable regu-
lations. Hepatic transaminases alanine
aminotransferase (ALT = GPT) and aspartate
aminotransferase (AST = GOT) were docu-
mented, if available, at baseline and in week 6
(W6), 12, 24, and 52, and in accordance with
the actual SmPC in 2012 (summary of product
characteristics) additionally after 3 weeks in the
VIVRE study. Recommended standard values for
ALT and AST were used in cases where specified
information was not available (50 U/I or
0.83 lmol/L for men; 35 U/I or 0.58 lmol/L for
women). Transaminase values ALT and AST
were classified as follows (ULN = upper limit of
normal range):
Normal, within normal range BULN
Abnormal, above normal range, but not
clinically relevant
[ULN and
B39 ULN
Abnormal,[3 times above normal
range, clinically relevant
[39 ULN
The limit for clinical relevance of transami-
nase elevations ([39 ULN) was defined in
accordance with FDA recommendations [35].
Transaminase values as well as ADRs were eval-
uated overall as well as separately for three
treatment phases (W0–12, W12–24, and
W24–52), considering acute, continuation, and
maintenance treatment.
Data Analysis
Data of all four studies are included in the main
analysis over 12 weeks. Patients with data at the
inclusion visit and at least one further visit were
eligible for statistical analysis of effectiveness
(n = 9283; 96.2%). All 9601 patients with
returned documentation forms were included
in the safety analysis (ADR surveillance). Doc-
umented hepatic transaminase values (ALT/
AST) were available for 9588 patients (at least
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one documented value), baseline and at least
one follow-up value of ALT/AST for 6443/6282
patients (67%/65%), and values at every visit for
5061/4956 patients (53%/52%). Exclusion cri-
teria for effectivity analysis were patients with-
out intake of agomelatine or retrospective
documentation.
Pooled analysis of CGI response and remis-
sion rates was performed for patients with valid
data at each respective visit, resulting in differ-
ent numbers of patients at each visit. A second
approach of analysis was implemented to vali-
date the results by evaluating only patients with
available values at every visit.
Additional analyses of the treatment effect
were performed in subpopulations over
24 weeks (VIVALDI follow-up/VITAL; n = 3610)
and 52 weeks (VIVALDI follow-up; n = 605) as a
result of the different duration of studies.
Long-term tolerability was analyzed accordingly
in the safety analysis for week 12–24 (VIVALDI
follow-up/VITAL: n = 3915) and week 24–52
(VIVALDI follow-up: n = 605).
Evaluation of body weight and BMI (body
mass index) are based on patients with a valid
assessment of height and weight at W0 and
weight at the respective follow-up visit (W12 or
W24). Therefore body weight and BMI were
analyzed over 12 weeks (VIVALDI/VIVALDI
Praxis/VIVRE: n = 5273 and 5271) and 24 weeks
(VITAL: n = 2687 and 2686, respectively).
The statistical analysis of pooled data was
performed descriptively because of the non-in-
terventional design of the individual studies
using SAS (version 9.2 for Microsoft Windows;
SAS Institute Inc., Cary, NC, USA). Quantitative
variables were evaluated using the basic statis-
tical parameters (mean value ± standard devia-
tion, median). For qualitative data (e.g., sex)
and categorical variables (e.g., scale values),
frequency distributions (absolute and relative
frequency) were drawn up. Adverse events were
coded according to MedDRA and evaluated on
the basis of the coding levels of ‘‘system organ
class’’ and ‘‘preferred terms’’.
Data management and statistical analysis
were performed by the independent statistical
institute GKM Gesellschaft fu¨r Thera-
pieforschung mbH.
Compliance with Ethics Guidelines
This current article is based on previously con-
ducted studies and does not involve any new
studies of human or animal subjects performed
by any of the authors.
All studies were conducted in accordance
with recommendations of the German
Medicines Act (AMG), the Federal Institute of
Drugs and Medical Devices (BfArM), the
Guidelines of the German Working Group for
Epidemiology (DAE) ensuring Good Epidemio-
logical Practice as well as recommendations of
the Association of Research-Based Pharmaceu-
tical Companies (VfA). All procedures followed
were in accordance with ethical standards, all
four individual studies were approved by the
Free Ethics Committee Freiburg, Germany,
submitted to German authorities (BfArM, KBV,
GKV-Spitzenverband), included in the inter-
national study registry http://www.controlled-
trials.com, and published [28–34]. All proce-
dures also followed the ethical standards of the
Helsinki Declaration of 1964, as revised in
2000 and 2008. Informed consent form was
requested from all patients before being
included in the original studies, but not
mandatory because of the non-interventional
design.
RESULTS
Patient Characteristics
Patient characteristics and demographic data
are shown in Table 1. The mean age of the
pooled population was 50.5 ± 13.4 years (69%
C45 years), 65.3% were female, and 60.2% of
patients had a recurrent depression. Mean
duration of the current episode was almost
11 weeks with the shortest duration reported
by GPs (6 weeks) and the longest by psychia-
trists (14 weeks). 72% of the pooled popula-
tion (n = 6674) showed psychiatric
comorbidities, most frequently sleep disorders
(56.6%), anxiety/panic disorder (35.5%),
post-traumatic stress disorder (7%), and others
(14%), with multiple entries possible. The
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Table 1 Demographics of the pooled analysis dataset (n = 9283) and individual studies. Modiﬁed with permission from
[36]
Pooled analysis
(n5 9283)
VIVALDI (n5 3317) VIVALDI Praxis
(n5 1070)
VITAL
(n5 3005)
VIVRE
(n 5 1891)W0–12
(n5 3317)
Follow-up
(n5 605)
Sex (%)
Male 34.7 35.5 35.0 34.1 34.0 35.1
Female 65.3 64.5 64.7 65.9 66.0 64.9
Age [years] (mean
value ± SD)
50.5 ± 13.4 50.5 ± 13.0 49.3 ± 12.5 52.7 ± 14.2 50.5 ± 13.6 50.3 ± 13.3
Age groups (%)
\25 years 2.9 3.1 3.2 2.2 3.1 2.8
25 to\45 years 28.2 29.1 31.4 26.8 27.6 28.8
45 to\65 years 54.5 54.4 54.5 50.7 55.3 55.5
65 to\75 years 10.2 11.0 8.8 13.0 9.3 8.4
C75 years 4.2 2.5 2.2 7.3 4.7 4.4
Duration of
observation
(weeks)
12 (24/52) 12 52 12 24 12
BMI [kg/m2] (mean
value ± SD)
26.4 ± 4.9 26.4 ± 4.9 26.3 ± 4.8 26.6 ± 4.8 26.4 ± 4.8 26.5 ± 4.9
Smoking status (%)
Smoker 27.2 28.2 22.6 29.4 25.3 27.6
Non-smoker 58.9 60.2 52.9 55.5 59.7 57.3
Ex-smoker 13.9 11.7 9.1 15.1 14.9 15.0
Diagnosis (%)
Depressive episode
(F32)
39.8 36.4 37.5 40.6 52.9 24.8
Recurrent
depression (F33)
60.2 63.6 62.0 59.4 47.1 75.2
Number of depressive episodes in the past history
Mean value ± SD 3.9 ± 6.1 4.5 ± 7.2 4.7 ± 7.1 4.2 ± 7.2 3.6 ± 5.4 3.2 ± 4.2
Median 2 3 3 2 2 2
Duration of the current depressive episode (weeks)
Mean value ± SD 10.6 ± 16.4 13.9 ± 21.3 11.8 ± 16.9 6.1 ± 7.4 8.9 ± 11.1 9.8 ± 15.9
Median 6 8 6 4 6 6
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lowest incidence of psychiatric comorbidities
(8.2%) was reported in VIVALDI Praxis (GP
study) (see Table 1).
After 12 weeks, 67.8% of patients were trea-
ted with agomelatine 25 mg/day (Table 2). In
the subpopulation over 24 weeks (VITAL/
VIVALDI follow-up) 72.6% of patients
(n = 1914/2637) were treated with 1 tablet/day
(25 mg). A dose increase was documented more
frequently by psychiatrists in the VIVALDI
study compared to GPs (VIVALDI Praxis) and
following studies (VITAL and VIVRE).
Psychotropic Co-medication
Overall, 60.1% of patients (n = 5581) were
already pretreated with antidepressants, 70.2%
in the VIVALDI study and 45.0% in VIVALDI
Praxis. SSRI (selective serotonin reuptake inhi-
bitors) were the most common medication in
pretreatment (31.4%). In 18.9% of patients,
previously prescribed antidepressants were
continued in addition to agomelatine.
At baseline, co-medication with other psy-
chotropic drugs was documented for 31.9% of
Table 1 continued
Pooled analysis
(n5 9283)
VIVALDI (n5 3317) VIVALDI Praxis
(n5 1070)
VITAL
(n5 3005)
VIVRE
(n 5 1891)W0–12
(n5 3317)
Follow-up
(n5 605)
Suicide attempts (%)
Yes 5.9 8.0 7.8 2.9 5.1 5.8
No 89.6 87.5 79.8 89.9 91.5 89.8
Unknown 4.4 4.5 3.6 7.2 3.5 4.4
Concomitant psychiatric illnesses (%)
Yes 71.9 70.4 64.6 8.2 84.4 90.7
No 28.1 29.6 35.4 91.8 15.6 9.3
Pretreatment (%)
Total 60.1 70.2 67.6 45.0 58.2 54.0
SSRI 31.4 49.1 36.9 19.7 27.1 28.5
TCA 23.2 32.1 31.5 17.0 20.7 15.7
Mirtazapine 15.2 21.0 17.9 9.6 13.2 11.5
SNRI 14.3 24.9 13.1 7.5 10.3 11.7
St. John’s wort 8.1 6.5 5.6 11.9 9.6 6.3
MAO inhibitor 1.6 2.9 3.6 0.6 1.4 0.5
Comedication (%)
Antidepressant 18.9 25.8 26.0 9.1 13.1 19.9
Other psychotropic
medication
31.9 30.1 26.8 31.7 4.1 39.1
Calculation based on the patients with data available at start of study
SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, SNRI serotonin–norepinephrine reuptake inhi-
bitor, MAO monoamine oxidase
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patients, most frequently zolpidem or zopiclone
(13.0%; n = 1204), benzodiazepines (10.1%;
n = 933), antipsychotics/neuroleptics (5.7%;
n = 531), anticonvulsant drugs (2.2%; n = 205),
and 6.7% others (multiple entries were possible)
(Table 1).
Change in Depressive Symptoms
The severity of depression (CGI-S) improved
over 12 weeks (VIVALDI, VIVALDI Praxis, and
VIVRE) with reduction of CGI-S (mean value)
from 4.7 ± 0.8 at baseline (5 = patient is signif-
icantly ill) to 3.0 ± 1.3 after 12 weeks (3 = pa-
tient is only mildly ill). Overall, there was
improvement of CGI-S in 81% of patients. As a
result of longer observation periods in the
studies VITAL and VIVALDI follow-up, the
effect on the severity of depression was also
analyzed after 6 months (W24). The pooled data
(n = 3350) demonstrate a decrease in mean
value of CGI-S from 4.7 ± 0.8 (W0) to 2.8 ± 1.3
(W24) (Fig. 1a), corresponding to an improve-
ment of severity of depression (CGI-S) in 82.4%
of patients after 24 weeks.
On the basis of the CGI-I score, 78.7% of
patients were classified as responders (CGI-I B2)
after 12 weeks and 79.3%/75.9% after
24/52 weeks, respectively; 34.5% of patients
met the criteria for remission (CGI-S = 1 or 2)
after 12 weeks and 38.1%/47.5% after
24/52 weeks (Fig. 1b).
Tolerability
Frequency and type of ADRs, including serious
ones (sADRs), were evaluated in the main
analysis safety set (n = 9601) over 12 weeks:
5.32% of patients (511 of 9601) reported 859
ADRs (8.9%), most frequently headache, nau-
sea, dizziness, and agitation; 0.49% of patients
(n = 19/3915) reported 28 ADRs between weeks
12 and 24, six patients (n = 6/605; 0.99%) with
seven ADRs between weeks 24 and 52. Head-
ache, dizziness, and agitation were no longer
reported after 24 weeks (Fig. 2a).
Eighteen patients (0.19%) reported 33 sADRs
within the first 12 weeks. Three sADRs were
documented in two patients (0.05%) between
weeks 12 and 24; one of these patients (0.03%)
had bradycardia and one patient (0.03%) had
symptoms of hepatobiliary disorder starting
after 10 weeks of treatment with agomelatine
50 mg/day. The hepatitis symptoms of this
Table 2 Patients (%) in the pooled dataset and individual studies according to agomelatine dosage over 12 weeks (W12).
Modiﬁed with permission from [36]
Visita Pooled analysis (%) VIVALDI (%) VIVALDI Praxis (%) VITAL (%) VIVRE (%)
25 mg
W0 98.4 98.9 98.7 97.9 98.0
W2b 74.2 68.7 82.4 77.3 73.9
W6 67.7 58.7 79.2 71.0 69.4
W12 67.8 58.3 79.7 70.5 70.6
50 mg
W0 1.4 1.0 1.1 1.7 1.8
W2b 25.4 30.9 17.5 22.2 25.9
W6 31.8 40.1 20.7 28.6 30.4
W12 31.5 40.4 20.0 29.0 29.0
a Analysis based on the following number of patients at each respective visit: n = 9067, W0; n = 8654, W2; n = 8026,
W6; n = 7805, W12
b In the VIVRE study dosage was documented after 3 weeks
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patient were completely reversible after dis-
continuation of treatment and the patient
recovered without persisting impairment or
sequelae. A detailed description of this patient
has already been published [36]. No serious
event occurred between weeks 24 and 52
(Table 3).
Regarding psychotropic co-medication,
ADRs were documented for 5.28% (n = 161) of
patients with (n = 3048) versus 5.34% (n = 350)
of patients without co-medication (n = 6553)
(Fig. 2b), showing no substantial difference in
relation to psychotropic co-medication.
sADRs were reported for 0.3% of patients
(n = 9) with psychotropic co-medication com-
pared to 0.14% of patients (n = 9) without
co-medication. The difference was mainly due
to reports of headache, somnolence,
Fig. 1 Change of depressive symptoms according to CGI
in the pooled dataset and individual studies over 12 weeks
(W12) and 24/52 weeks (W24/52; subpopulations): a im-
provement of severity (CGI-S; mean value ± standard
deviation). Asterisk indicates CGI-S values not available in
VITAL study after 12 weeks (study duration 24 weeks),
b response (CGI-I B2) and remission (CCI-S = 1 or 2) in
%. CGI Clinical Global Impression scale, CGI-S (severity
scale), CGI-I (improvement scale); assessment of all
patients with available data at each respective visit; # in
VIVRE study data were documented after 3 weeks Mod-
iﬁed with permission from [36]
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aggression, dissociation, hallucination, insom-
nia and mania (one report for each symptom),
and depression (n = 2) in co-medicated
patients compared to no reports in patients
without co-medication. For one patient of
each group (with/without co-medication),
transaminase elevations were assessed as
sADRs (corresponding to 0.03%/0.02%). No
deaths occurred and no long-term impairment
was observed in the total population
(n = 9601).
Change in Hepatic Values
Overall, 9588 patients with liver transaminase
values (at least one value available) were inclu-
ded in this analysis. At baseline, hepatic
transaminases (ALT and AST) were documented
for 78.4% (n = 7517) and 76.4% (n = 7321) of
all patients. Most of these patients showed ALT/
AST values within the normal range (BULN;
88.4%/90.8%) or a mild increase without clini-
cal relevance (B39 ULN; 11.4%/9.0%). In 0.2%
Fig. 2 Tolerability according to most frequent ADRs in
the course of treatment: a evaluation over 12 weeks,
between 12–24 and 24–52 weeks, b incidence of ADR
regarding psychotropic co-medication over 12 weeks. ADR
adverse drug reactions, W week, ULN upper limit of
normal range, [3 ULN clinically relevant elevation of
transaminases; cutoff for incidence over 12 weeks[0.25%;
asterisk indicates multiple entries were possible
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(ALT) and 0.1% (AST) of patients, a clinically
relevant increase ([39 ULN) had already been
documented before the start of treatment
(Fig. 3).
In comparison of individual studies, values
of liver function tests (ALT/AST) were available
at every visit in 60.3% (ALT) and 58.9% (AST)
of patients treated by GPs and 41.2% and
40.4% of patients treated by psychiatrists.
Between 2009 and 2013, the proportion of
documented values (ALT/AST) at every visit
increased from 41.2%/40.4% up to 54.9%/
53.9%. Accordingly, the proportion of docu-
mented values at baseline and at least one
follow-up visit increased from 54.9%/53.5% to
76.4%/74.6% of patients.
Overall, clinically relevant transaminase ele-
vations ([39 ULN) were documented in 0.5% of
patients (n= 49/9601), 0.2% (n = 19) of whom
showed clinically relevant ALT/AST elevations
before the treatment with agomelatine at the
study start (Table 4) and 30 patients (0.3%) an
increase of values ([39ULN) during treatment. In
a calculation according to per protocol analysis
(inclusionofpatientswithavailablevaluesatevery
visit), 30 patients with elevations under treatment
correspond to 0.6% and 23 patients with at least a
possible causal link (ADR) to 0.46%. There was no
difference in the incidence of transaminase ele-
vations with respect to psychotropic co-medica-
tion (0.33%/0.32% of patients with/without
psychotropic co-medication).
Table 3 Number (n) and percentage (%) of patients with serious adverse drug reactions (sADR) within different treatment
periods (week 0–12/12–24/24–52), based on the safety analysis set (SAS) of each respective period. Modiﬁed with
permission from [36]
sADRa W0–W12 (n5 9601) W12–W24 (n5 3915) W24–W52 (n5 605)
Patients Patients Patients
n % n % n %
Any 18 0.19 2 0.05 – –
Diarrhea 1 0.01 – – – –
General disorders 2 0.01 – – – –
Hepatic investigations 2 0.01 – – – –
Headache 1 0.01 – – – –
Somnolence 1 0.01 – – – –
Psychiatric disorders 13 0.14 – – – –
Anxiety 2 0.02 – – – –
Depression 2 0.02 – – – –
Restlessness 2 0.02 – – – –
Sleep disorder 2 0.02 – – – –
Suicidal ideation 9 0.09 – – – –
Others 8 0.08 – – – –
Hospitalization 1 0.01 – – – –
Bradycardia – – 1 0.03 – –
Hepatobiliary disorders – – 1 0.03 – –
a Multiple responses possible
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Transaminase elevations were classified as
ADRs in 23 patients (with at least possible
causal relationship). Almost 80% of affected
patients were between 25 and 65 years of age
(4.4% [75 years). Detailed patient charac-
teristics of affected patients are listed in
Fig. 4.
Over 12 weeks of treatment, 11 patients
(0.2%) with normal baseline values developed
ALT elevations and 7 patients (0.1%) AST ele-
vations ([39 ULN). In patients with slight ele-
vations at baseline, 0.1% showed clinically
relevant elevations of ALT (n = 7) and/or AST
(n = 5), respectively.
Fig. 3 Patients’ hepatic transaminase values (ALT and
AST) during the course of treatment over 12 weeks (main
analysis) and 24/52 weeks (subpopulations). ALT alanine
aminotransferase, AST aspartate aminotransferase, [3
ULN[3 times above normal range; transaminase mon-
itoring after 3 weeks was documented in VIVRE study
only, according to the actual summary of product
characteristics (3/2012) at time of study implementation
Table 4 Clinically relevant transaminase elevations (ALT and/or AST[3ULN) and documentation status of adverse drug
reactions (ADR)
ALT – AST elevations >3 ULN Patients
(W0–W52) (n)
Reference population for calculation (%)
Total population
(n5 9588)
Per protocol (ALT 5 5061;
AST 5 4956)
Patients with baseline elevation (i.e.,
preexisting elevations)
19 0.19 0.38
Elevation during treatment 30 0.31 0.60
ADRs (with at least possible causality) 23 0.24 0.46
No ADR (without causal relationship) 7 0.07 0.14
Total number (including preexisting
elevations)
49 0.51 0.98
Calculation of percentage based on total population (with at least one liver function test) or patients with available
transaminase values at every visit (corresponding to ‘‘per protocol’’). Modiﬁed with permission from [36]
ALT alanine aminotransferase, AST aspartate aminotransferase;[3 ULN[3 times above normal range
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Evaluating liver function in long-term ther-
apy, 0.04% of the patients with normal
transaminase values at the beginning of treat-
ment developed a relevant ALT and/or AST
elevation ([39 ULN) over 24 weeks (n = 1/
2437) and 0.3% (n = 1/288) over 52 weeks. Two
patients with slightly elevated values (B39
ULN) at the study start showed an ALT elevation
([39 ULN) over 24 weeks (0.1%) and no patient
over 52 weeks (available values W0–W24,
n = 2437/2387; W0–W52, n = 288/282). Addi-
tionally, no patient with normal or slightly
elevated transaminase values at week 12
developed a clinically relevant increase in ALT
or AST ([39 ULN) during further treatment.
Body Weight
Mean weight was 76.9 kg (±15.7) at the begin-
ning of the observation period and 77.0 kg
(±15.5) after 12 weeks. Corresponding values
for the BMI were 26.4 ± 4.9 kg/m2 (W0) and
26.5 ± 4.8 kg/m2 (W12). Also after 24 weeks, the
evaluated subpopulation (VITAL study) did not
show any relevant changes in body weight or
BMI (Fig. 5).
Fig. 4 Patient characteristics of the 23 patients with
clinically relevant elevation of hepatic transaminases
(ADR): a gender, age, used dosage, status of co-medication
and reversibility; b patients (%) according to their duration
of treatment until onset of ALT/AST elevation ([3
ULN). ADR adverse drug reaction, m male, f female,[3
ULN[3 times above the normal range; calculation based
on pharmacovigilance data of patient reports; asterisk
indicates no information available for dosage (n = 1;
4.4%), co-medication (n = 4; 17.4%), reversibility (n = 3;
13.0%)
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DISCUSSION
The presented analysis of naturalistic observa-
tional data provides important epidemiological
data in a large number of non-selected patients
(n = 9601). The findings demonstrate the effec-
tiveness and good tolerability profile of
agomelatine, which is in line with proven effi-
cacy and tolerability in various RCTs [21, 26]. In
the observational VIVALDI study [31] this effect
was also demonstrated independent of psy-
chotropic co-medication, which is confirmed in
the presented mixed patient cohort.
Demographic data of the evaluated depres-
sed population are representative of daily med-
ical care with a high proportion of pretreated
and comorbid patients [37]. Severity of depres-
sion was more pronounced in patients treated
by specialists, reflected by the proportion of
psychiatric comorbidities, co-medication,
number and duration of depressive episodes as
well as previous suicide attempts.
More than two-thirds of this large sample
used agomelatine 25 mg/day (1 tablet) over 12
and 24 weeks, being in line with controlled data
where about 75% of patients were medicated
with 25 mg/day [38]. A dose increase in the
presented patient cohort was documented more
frequently by psychiatrists compared to GPs
(VIVALDI Praxis), possibly as a result of more
pronounced severity of depression and higher
incidence of psychiatric comorbidities and
co-medication in specialists’ practices.
In the present analysis, the CGI scale was
used as an indicator for effectiveness, repre-
senting a general assessment of severity and
improvement of depression by physicians. The
CGI usually corresponds well with treatment
effects evaluated with more specific scales
(MADRS, Montgomery-Asberg Depression Rat-
ing Scale; Hamilton Depression Scale, HAM-D)
in clinical and observational studies [31, 38, 39].
In the VIVALDI and VIVALDI Praxis trials, the
short version MADRS (svMADRS) [40] was used
in addition to CGI and confirmed CGI results,
also being comparable to RCT data. Improve-
ment according to CGI in our sample can
therefore be seen as an indication for effective-
ness of agomelatine with response and remis-
sion rates supporting the results of controlled
data [38, 39]. Moreover, the antidepressant
effect in this outpatient setting can also be
evaluated in the continuation and maintenance
phase of treatment, representing meaningful
information in addition to clinical trials over
6–12 weeks, owing to a placebo control arm
being included.
The overall incidence of ADRs in our unse-
lected patient population is low with a known
profile of adverse events (especially headache,
nausea, dizziness). No new information was
obtained about previously unknown ADRs
compared to the existing database of controlled
trials or non-interventional studies. Most ADRs/
sADRs were documented within the first weeks
of treatment and markedly decreased after
Fig. 5 Evolution of a body weight (kg) and b BMI (kg/m2) over 12 weeks (VIVALDI, VIVALDI Praxis, VIVRE) and
24 weeks (subpopulation of VITAL). Evaluation of patients with valid data at baseline and W12 or W24, respectively
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12 weeks. sADRs were no longer reported after
week 24. Interestingly, ADRs and sADRs occur-
red nearly independent of psychotropic
co-medication. Taken together, the presented
results confirm data of clinical trials considering
tolerability without effects on sexual function
or cardiovascular parameters and a favorable
interaction profile with emergence of ADRs
primarily at the beginning of treatment [11].
In our large sample, no relevant changes of
body weight occurred during short-term treat-
ment or over 24 weeks. These results are in good
agreement with possible positive metabolic
effects of agomelatine described in several
studies [41, 42]. A specific receptor profile
without affinity to other receptors (especially
no anti-histaminergic effect), normalization of
circadian rhythms by melatonergic effects, and
a positive influence on cortisol levels could
serve as an explanation. These characteristics of
the substance seem relevant, since weight gain
is a frequently observed undesired effect with
psychotropic medication [43].
In order to investigate the influence of
agomelatine treatment on liver function,
transaminase values were documented in all
four studies. For the present pooled analysis,
transaminase values (ALT/AST) were available
for about half of the patients at every visit and
for about two-thirds of all patients at baseline
and at least one further follow-up visit. Com-
parison of the included individual studies con-
firms the assumption that transaminase
monitoring is performed more often by GPs
compared to psychiatrists. Besides, the increas-
ing proportion of documented transaminase
values over time between 2009 and 2013 is
shown, presumably correlating with increasing
awareness of physicians concerning transami-
nase monitoring in agomelatine-treated
patients. Overall, clinically relevant elevations
of ALT and/or AST ([39 ULN) were docu-
mented for 49 patients (0.5%), 19 (0.2%) of
whom already showed elevations before the
beginning of medication, hence not being
classified as ADR. Transaminase values generally
normalized after discontinuation of agome-
latine, in some cases even during continuation
of treatment, which is in line with RCT data
[22, 23, 44]. One patient with symptoms of
hepatitis and icterus recovered without any
further impairment after discontinuation of
treatment. A detailed case description has pre-
viously been published [36]. Before treatment
initiation, only incomplete laboratory values
were available for this patient, further support-
ing the importance of transaminase monitoring
before medication, and thereby improving risk
detection of preexisting impaired liver function.
It is worth mentioning that no case of acute
liver failure occurred under controlled condi-
tions with strictly requested blood tests in RCTs
in nearly 8000 patients [44].
Presented pooled data show a lower inci-
dence rate of clinically relevant elevations
compared to numerous controlled trials
[11, 22, 23, 44]. Recruitment practice could
possibly account for a higher incidence in RCTs,
especially compared to American studies with
more patients having preexisting risk factors
(e.g., hepatobiliary disorder) [23, 45]. Strict
clinical monitoring under controlled conditions
could also explain higher reporting rates in
RCTs compared to this naturalistic design. The
demonstrated lower incidence in this pooled
data set, however, is verified by an additional
analysis based on patients with available values
at every visit (ALT, n = 5061; AST, n = 4956).
This additional calculation (comparable to ‘‘per
protocol’’ analysis) confirms lower incidence
rates of transaminase elevations (ADRs) in
23 patients corresponding to 0.46% and of all
documented cases including preexisting base-
line elevations with 0.98% (n = 49).
Various database analyses have been pub-
lished so far, investigating spontaneous reports
of adverse hepatic effects during agomelatine
treatment [46–48], to explore quantitative sig-
nals about reporting frequencies without
causality assessments, since reports listed in
safety databases are ‘‘raw data’’ [49]. Gahr and
colleagues describe that hepatic effects in
agomelatine-treated patients (mostly asymp-
tomatic transaminase increase) occur primarily
in the initial phase of treatment. Polypharmacy,
female gender, and age over 50 years were
described as possible risk factors [46].
Our results confirm the emergence of
transaminase elevations within the first weeks
of treatment, reversibility, and increased
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occurrence in women and patients with
co-medication. Older age, however, did not
correlate with higher risk of transaminase
abnormalities in our population with two-thirds
of the patients being younger than 55 years.
This result is confirmed by RCT data,
demonstrating good tolerability in older
patients up to 6 months of treatment [50, 51]
without the necessity for dose adjustment in
elderly patients [11]. Higher incidence of
transaminase elevations in women within this
sample could possibly be explained by the high
proportion of women in the depressed popula-
tion in general. Nevertheless, even taking base-
line data into account with a ratio of 2:1
(female/male), the presented results still show a
trend for a higher frequency in women.
With the objective of ensuring therapeutic
safety, the European Medicines Agency (EMA)
has developed increasingly rigorous criteria
regarding quality of studies and especially
pharmacovigilance procedures. Regular moni-
toring of various blood tests, ECG (electrocar-
diogram), EEG (electroencephalography), or
other controls are required or recommended for
many antidepressants or psychotropic drugs in
guidelines, standard references, and textbooks
[37, 47, 52, 53].
In this context, monitoring of hepatic
transaminases is listed in the SmPC of agome-
latine and should be performed before the ini-
tiation of treatment, after approximately 3, 6,
12, and 24 weeks, after emergence of clinical
symptoms of hepatic dysfunction, and after a
dose increase [11].
Considering the general risk of possible
drug-related liver damage during treatment
with psychotropic drugs, monitoring of liver
function tests is recommended in general
[11, 37, 47, 52, 54, 55]. Thereby therapeutic
safety as well as early detection of patients at
risk with preexisting relevant diseases can be
improved, especially in case of polypharmacy
[37, 52, 54–57].
Limitations
An important limitation to be mentioned is the
non-interventional, open-label, observational
design of the four individual studies included in
the present pooled analysis, with lack of ran-
domization, blinding, and placebo control
group. Therefore the observational design
might lead to an overestimation of therapeutic
effects compared to RCTs. Controlled studies
with strict inclusion/exclusion criteria, how-
ever, do not represent naturalistic patient pop-
ulations with comorbidities and co-medication,
which underlines the relevance of non-inter-
ventional studies. Even though observational
trials are not able to provide proof of efficacy
because of methodological reasons, they
nonetheless provide important information of
everyday clinical practice. The notable strength
of the presented pooled analysis is the large
number of non-selected patients.
Potential underestimation of adverse drug
reactions due to possible underreporting can
not be completely ruled out. As a result of the
non-interventional design, ADRs were not
assessed systematically but were documented in
the form of open questions at each visit. Con-
sidering data of controlled studies, however,
type, severity, and time of emerging ADRs
within our presented pooled data are in line
with the tolerability profile demonstrated in
RCTs.
Short duration of individual studies over
3 months is a further limitation worth being
discussed. The main analysis of pooled data was
performed after 12 weeks, thereby representing
short-term treatment. However, this correlates
well with the duration of RCTs between 6 and
12 weeks. Besides, a subgroup over 24 weeks
with more than 3000 patients was additionally
analyzed in this pooled dataset, providing rele-
vant data for continuation treatment in unse-
lected patients.
Another limitation to be mentioned is the
mixed nature of data due to significant differ-
ences in investigators. In the presented pooled
analysis the treatment effect of agomelatine has
been evaluated rather generally by means of the
CGI as a less specific scale compared to more
detailed scales used in psychiatry. Besides, GPs
in VIVALDI Praxis were offered a rater training
(like psychiatrists in the VIVALDI study) via a
video test version of the more complex
svMADRS questionnaire to ensure a high
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quality of collected data. Concerning the anal-
ysis of tolerability, the specialization of doctors
should probably generate only minor differ-
ences. According to the objective of gaining
information about psychiatric care in daily
routine, the strength of the actual pooled
analysis is the large sample of comorbid and
co-medicated patients of daily practice, as in
German psychiatric care the intersectoral treat-
ment situation between hospital care and out-
patient treatment (by specialists and/or GPs) is
an actual and important issue.
As a result of possible differences in the point
of view on psychiatric disorders between the
two groups of physicians, separate results for
psychiatrists and GPs would have been infor-
mative. In conformity with the statistical anal-
ysis plan (SAP) and the stated objective of
analyzing a large sample of naturalistic psychi-
atric patients as an overall group, stratified data
analysis according to doctors’ specialization has
not yet been performed. However, baseline
data, dosage, and evolution of depressive
symptoms by means of CGI are presented in the
total population and on the basis of individual
studies, thereby allowing a first insight into this
interesting question. Further evaluation of this
large database with a focus on stratification
could offer an additional objective for a
prospective data analysis.
CONCLUSION
In the presented pooled analysis of four
prospective open-label studies, agomelatine
demonstrated good clinical effectiveness and
tolerability in a heterogeneous patient cohort
(n = 9601) over 12 weeks and over 24/52 weeks
(subpopulations). Overall improvement of
depressive symptoms is demonstrated in CGI
response and remission rates. The incidence of
adverse drug reactions is low (5.3%), irrespec-
tive of psychotropic co-medication, and no new
information about previously unknown or very
rare ADR is obtained. Additionally, the results
provide naturalistic information about poten-
tial effects of agomelatine on liver function,
mainly observed in the form of reversible
transaminase elevations and primarily observed
within the first 12 weeks. Presented data con-
firm current recommendations for transaminase
monitoring, especially during the first months
of treatment.
In summary, the pooled data analysis reflects
effectiveness and tolerability of agomelatine,
supplementary to clinical trials, and indepen-
dent of psychotropic co-medication in non-se-
lected patients of daily clinical practice.
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